Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 594 participants.
Also called NCT01887600
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 594 participants
- Registry
-
NCT01887600 -
2012-005180-27
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belarus, Belgium, Bulgaria, Colombia, Dominican Republic, Estonia, Georgia, Greece, Guatemala, Hungary, Italy, Panama, Peru, Poland, Romania, Russia, Serbia, South Africa, Spain, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01887600. Randomized; quadruple masking; primary purpose treatment. Start 2013-09-03 (actual); primary completion 2017-11-01 (actual). Results posted on 2020-12-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
- Acronym
- ALPS
- Condition
- Anemia in Chronic Kidney Disease in Non-dialysis Patients
- Intervention (Drug)
- Roxadustat
- Intervention (Drug)
- Placebo
- Lead sponsor
- Astellas Pharma Europe B.V.
- Collaborator
- Kyntra Bio
Record details
- Record id
cardio:ct-nct01887600- Content hash
94d7528cd45a4128ba84518152befc5a7db7e9979bcdc9fd35b9e111f3f05397